Ophthalmic composition

1. An ophthalmic composition, comprising:

from about 0.001 wt % to about 0.05 wt % of a muscarinic antagonist;

a buffer agent; and

deuterated water;

wherein the muscarinic antagonist is atropine or atropine sulfate.

2. The ophthalmic composition of claim 1 , wherein the ophthalmic composition has a pD of from about 4.2 to about 7.9.

3. The ophthalmic composition of claim 1 , wherein the ophthalmic composition has a pD of one of: less than about 7.3, less than about 7.2, less than about 7.1, less than about 7, less than about 6.8, less than about 6.5, less than about 6.4, less than about 6.3, less than about 6.2, less than about 6.1, less than about 6, less than about 5.9, less than about 5.8, less than about 5.2, or less than about 4.8 after extended period of time under storage condition.

4. The ophthalmic composition of claim 1 , wherein the ophthalmic composition comprises one of: at least about 80%, at least about 85%, at least about 90%, at least about 93%, at least about 95%, at least about 97%, at least about 98%, or at least about 99% of the muscarinic antagonist based on initial concentration after extended period of time under storage condition.

5. The ophthalmic composition of claim 1 , wherein the ophthalmic composition further has a potency of one of: at least 80%, at least 85%, at least 90%, at least 93%, at least 95%, at least 97%, at least 98%, or at least 99% after extended period of time under storage condition.

6. The ophthalmic composition of claim 1 , wherein the ophthalmic composition is stored for an extended period of time comprising one of: about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 8 months, about 10 months, about 12 months, about 18 months, about 24 months, about 36 months, about 4 years, or about 5 years.

7. The ophthalmic composition of claim 1 , wherein the ophthalmic composition is stored at a storage temperature of from about 2° C. to about 10° C. or from about 16° C. to about 26° C.

8. The ophthalmic composition of claim 1 , wherein the muscarinic antagonist is present in the composition at a concentration of one of: from about 0.001 wt % to about 0.04 wt %, from about 0.001 wt % to about 0.03 wt %, from about 0.001 wt % to about 0.025 wt %, from about 0.001 wt % to about 0.02 wt %, from about 0.001 wt % to about 0.01 wt %, from about 0.001 wt % to about 0.008 wt %, or from about 0.001 wt % to about 0.005 wt %.

9. The ophthalmic composition of claim 1 , wherein the buffer agent is selected from borates, borate-polyol complexes, phosphate buffering agents, citrate buffering agents, acetate buffering agents, carbonate buffering agents, organic buffering agents, amino acid buffering agents, or combinations thereof.

10. The ophthalmic composition of claim 1 , wherein the ophthalmic composition further comprises a preservative, an osmolarity adjusting agent, or a combination thereof.

11. The ophthalmic composition of claim 1 , wherein the ophthalmic composition is essentially free of procaine and benactyzine, or pharmaceutically acceptable salts thereof.

12. The ophthalmic composition of claim 1 , wherein the ophthalmic composition further comprises a pD adjusting agent selected from deuterated hydrochloric acid, deuterated sodium hydroxide, deuterated acetic acid, or deuterated citric acid.

13. The ophthalmic composition of claim 1 , wherein the ophthalmic composition comprises one of: less than 5% of H 2 O, less than 4% of H 2 O, less than 3% of H 2 O, less than 2% of H 2 O, less than 1% of H 2 O, less than 0.5% of H 2 O, less than 0.1% of H 2 O, or 0% of H 2 O.

14. The ophthalmic composition of claim 1 , wherein the muscarinic antagonist is a deuterated muscarinic antagonist.

15. The ophthalmic composition of claim 1 , wherein the ophthalmic composition is formulated:

for topical administration;

as an eye drop;

as a mucus penetrating particle formulation; or

as an ophthalmic gel or an ophthalmic ointment.

16. A method of treating an ophthalmic disorder or condition in an individual in need thereof, comprising administering to an eye of the individual an effective amount of an ophthalmic composition of claim 1 , wherein the ophthalmic disorder or condition is pre-myopia, myopia, or progression of myopia.

17. The method of claim 16 , wherein the ophthalmic composition is formulated as a non-injectable formulation.

18. An ophthalmic composition, comprising from about 0.001 wt % to about 0.05 wt % of a muscarinic antagonist and deuterated water, wherein the muscarinic antagonist is atropine or atropine sulfate, and wherein the ophthalmic composition is substantially free of tropic acid.

19. The ophthalmic composition of claim 18 , wherein the ophthalmic composition has a pD of from about 4.2 to about 7.9.

20. The ophthalmic composition of claim 18 , wherein the ophthalmic composition has a pD of one of: less than about 7.3, less than about 7.2, less than about 7.1, less than about 7, less than about 6.8, less than about 6.5, less than about 6.4, less than about 6.3, less than about 6.2, less than about 6.1, less than about 6, less than about 5.9, less than about 5.8, less than about 5.2, or less than about 4.8 after extended period of time under storage condition.

21. The ophthalmic composition of claim 18 , wherein the ophthalmic composition comprises one of: at least about 80%, at least about 85%, at least about 90%, at least about 93%, at least about 95%, at least about 97%, at least about 98%, or at least about 99% of the muscarinic antagonist based on initial concentration after extended period of time under storage condition.

22. The ophthalmic composition of claim 18 , wherein the ophthalmic composition further has a potency of one of: at least 80%, at least 85%, at least 90%, at least 93%, at least 95%, at least 97%, at least 98%, or at least 99% after extended period of time under storage condition.

23. The ophthalmic composition of claim 18 , wherein the ophthalmic composition is stored for an extended period of time comprising one of: about 1 week, about 2 weeks, about 3 weeks, about 1 month, about 2 months, about 3 months, about 4 months, about 5 months, about 6 months, about 8 months, about 10 months, about 12 months, about 18 months, about 24 months, about 36 months, about 4 years, or about 5 years.

24. The ophthalmic composition of claim 18 , wherein the ophthalmic composition is stored at a storage temperature of from about 2° C. to about 10° C. or from about 16° C. to about 26° C.

25. The ophthalmic composition of claim 18 , wherein the muscarinic antagonist is present in the composition at a concentration of one of: from about 0.001 wt % to about 0.04 wt %, from about 0.001 wt % to about 0.03 wt %, from about 0.001 wt % to about 0.025 wt %, from about 0.001 wt % to about 0.02 wt %, from about 0.001 wt % to about 0.01 wt %, from about 0.001 wt % to about 0.008 wt %, or from about 0.001 wt % to about 0.005 wt %.

26. The ophthalmic composition of claim 18 , wherein the ophthalmic composition further comprises an osmolarity adjusting agent, a preservative, or a buffer agent.

27. The ophthalmic composition of claim 18 , wherein the ophthalmic composition is essentially free of procaine and benactyzine, or pharmaceutically acceptable salts thereof.

28. The ophthalmic composition of claim 18 , wherein the muscarinic antagonist is a deuterated muscarinic antagonist.

29. The ophthalmic composition of claim 18 , wherein the ophthalmic composition is formulated:

for topical administration;

as an eye drop;

as a mucus penetrating particle formulation; or

as an ophthalmic gel or an ophthalmic ointment.

30. The ophthalmic composition of claim 18 , wherein the ophthalmic composition is formulated as a non-injectable formulation.